ArticleRadiation oncology (London, England)2026
Evaluation of the updated 2022 lung-GPA in NSCLC adenocarcinoma patients with brain metastases: analysis of prognostic factors in a German clinical cohort.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most frequent source of brain metastases (BMs), with 20-40% of patients with non-small cell lung cancer (NSCLC) developing BMs during the course of disease. The NSCLC-GPA (Graded Prognostic Assessment), developed by Sperduto et al., aims to estimate overall survival (OS) in lung cancer patients with BMs based on multiple prognostic factors. This study aimed to validate the applicability and prognostic relevance of the updated 2022 NSCLC-GPA in a German clinical cohort, with particular attention to programmed death-ligand 1 (PD-L1) expression and treatment-related outcomes.
methodsWe retrospectively analyzed patients with NSCLC and BMs treated between 2020 and 2022 at a German university hospital. GPA scores were calculated using established parameters: age, Karnofsky Performance Status (KPS), number of BMs, presence of extracranial metastases (ECM), EGFR and ALK mutation status, and PD-L1 expression. Due to the low number of non-adenocarcinoma (NAC) cases in our cohort, only patients with adenocarcinoma (AC) were included. Univariate and multivariate Cox regression models, log-rank tests, and Kaplan–Meier curves for illustrative purposes were used to evaluate associations between prognostic factors and OS.
resultsA total of 110 AC patients met the inclusion criteria. Median OS was 10 months (range: 6-11). Patients with GPA scores of 0-1 and 1.5-2 had significantly worse outcomes compared with the reference group (GPA 3.5-4; median OS: 36 months), with median OS times of 3 and 8 months, respectively (HR: 8.34, 95% CI: 2.53-27.5, p = 0.0005 and HR: 5.24, 95% CI: 1.584-17.33, p = 0.0067). Patients with a GPA of 2.5-3 had a median OS of 22.5 months (HR: 1.6, 95% CI: 0.469-5.45, p = 0.453), which was not statistically significant. Older age (≥ 70 years; HR: 1.95, 95% CI: 1.23-3.11, p = 0.0047), low KPS (KPS ≤ 70; HR: 3.88, 95% CI: 2.33-6.46, p < 0.0001), a higher number of BMs (HR: 1.58, 95% CI: 1.03-2.41, p = 0.035), and the presence of ECM (HR: 2.62, 95% CI: 1.66-4.13, p < 0.0001) were all significantly associated with decreased OS. In the multivariate analysis, low KPS and ECM remained independently significant prognostic factors. PD-L1 expression showed no significant association with OS.
conclusionDespite shorter OS outcomes in our cohort, the 2022 NSCLC-GPA proved to be a valuable prognostic tool, with lower scores consistently associated with poorer outcomes. In addition, older age, low KPS, ECM, and a higher number of BMs were identified as prognostic factors, with low KPS and ECM remaining independent prognostic factors in the multivariate analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.